Dr. James Del Giorno, MD

Medical School - Pennsylvania State University

Baylor College of Medicine, Residency in Internal Medicine

Baylor College of Medicine, Fellowship in General Cardiology

American Board of Internal Medicine

Cardiovascular Disease (Internal Medicine)

American College of Cardiology

2001: AVALON Trial – “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Open-Label Evaluation Of The Safety And Efficacy Of Dual Therapy With Atorvastatin Plus Amlodipine When Compared To Either Therapy Alone In The Treatment of Patients With Simultaneous Hyperlipidemia And Hypertension”

2000: SPORTIF V – An Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H 376/95 Compared with Dose-Adjusted Warfarin (Coumadin®) in the Prevention of Stroke and Systemic Embolic Events in patients with Atrial Fibrillation. Sub-Investigator.

1999: GUSTO IV AMI Trial – A Phase III Randomized, Open-Label Trial Evaluating The Efficacy And Safety Of ReoPro7 (Abciximab) In Combination With Reduced Dose Retavase7/RapilysinJ (Recombinant Plasminogen Activator, Reteplase, r-PA) For The Treatment Of Acute Myocardial Infarction. Sub-Investigator

1999: VALIANT Trial – Valsartan In Acute Myocardial Infarction Trial. A multinational, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high risk patients after myocardial infarction. Sponsored by Novartis Pharmaceuticals Corporation. Sub-Investigator.

1995: Prognostic Significance of Dobutamine Stress echocardiogram.

Male

#1841267028